Clinical Trials Logo

Everolimus clinical trials

View clinical trials related to Everolimus.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03014297 Terminated - Clinical trials for Neuroendocrine Tumors

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Start date: March 6, 2017
Phase: Phase 1
Study type: Interventional

This is a single center, open label, phase I study involving grade I-III gastroenteropancreatic neuroendocrine tumors, consisting of a dose escalation Part A followed by an expansion cohort Part B. On Part A Patients will be treated with daily oral everolimus. Fosbretabulin will be administered IV either q3 weekly or q weekly based on PO CRM cohort. Part B: Once the investigators have established an MTD in Part A, the investigators will be treating 15 more patients at that dose combination. The primary and secondary objectives of the expansion cohort will be similar to Part A of the study, i.e., to establish a safety profile of the experimental drug combination and to collect and assess efficacy data. Patients will be treated with concurrent everolimus and fosbretabulin for 12 weeks.